Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ROS1 fusion ROS1 G2032R |
| Therapy | ANS03 |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ROS1 fusion ROS1 G2032R | Advanced Solid Tumor | predicted - sensitive | ANS03 | Preclinical | Actionable | In a preclinical study, ANS03 treatment resulted in tumor regression in a cell line transplant model harboring a ROS1 fusion with ROS1 G2032R (Cancer Res (2025) 85 (8_Supplement_1): 828). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Abstract 828: ANS03, a novel, orally bioavailable small-molecule type II ROS1/NTRK inhibitor, effectively overcomes clinically relevant ROS1/NTRK resistance mutations and exhibits potent antitumor activity in preclinical tumor models | Full reference... |